May 5, 2000
On April 12 the European Agency for the Evaluation of Medicinal Products (EMEA) issued a warning on risks of severe or life-threatening skin or liver reactions to nevirapine, requiring precautions especially for patients starting the drug, during their first 8 weeks of treatment. The full public statement is available at: http://www.eudra.org/humandocs/PDFs/PS/1126000EN.pdf
In the U.S., some but not all of this information is already in the drug labeling, and new data from clinical trials is being analyzed to fine-tune any additional warnings required.
ISSN # 1052-4207
Copyright 2000 by John S. James. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used.
Back to the AIDS Treatment News May 5, 2000 contents page.